SAFETY AND EFFICACY OF AMBISOME VS CONVENTIONAL AMPHOTERICIN B IN THE TREATMENT OF PATIENTS WITH SUSPECTED OR CONFIRMED MYCOSIS

INTERVENTION: Systemic treatment of mycosis with either liposomal amphotericin B (AmBisome by Gilead Sciences) or conventional amphotericin B (Fungizone by Bristol‐Myers Squibb). Treatment will be given for a minimum of 14 days. However, if the patient's condition deteriorates after 10 days of therapy, the patient will be switched to salvage therapy (AmBisome 5mg/kg/day). TOtal duration of therapy depends on the infection and the patient's condition. CONDITION: Mycosis ‐ an invasive fungal infections PRIMARY OUTCOME: Primary endpoint is the rate of treatment related adverse events SECONDARY OUTCOME: Microbiological & Clinical Evaluation measured during double blind period and rescue period. INCLUSION CRITERIA: Highly suspected or confirmed invasive fungal infection.